Antisense Inhibition of Prekallikrein to Control Hereditary Angioedema
Danny M. Cohn, Nicholas J. Viney, Lauré M. Fijen, Eugene Schneider, Veronica Alexander, Shuting Xia, Gwendolyn E. Kaeser, Charvi Nanavati, Brenda F. Baker, Richard S. Geary, Marcel Levi, Joost C.M. Meijers, Erik S G Stroes
Abstract
at a dose of 80 mg every 3 to 4 weeks for 7 to 8 months. Treatment was accompanied by a reduction in the angioedema attack rate. (Funded by Amsterdam UMC.).
Topics & Concepts
Hereditary angioedemaPrekallikreinMedicineGeneticsKallikreinBiologyDermatologyBiochemistryEnzymeCoagulation, Bradykinin, Polyphosphates, and AngioedemaAutoimmune Bullous Skin DiseasesUrticaria and Related Conditions